REGISTER HERE
Webinar Description:
Cannabidiol (CBD) products are often marketed for a range of different health conditions; however, there is little evidence to support the safety and effectiveness of over-the-counter, non-FDA-approved CBD products for many of these uses. This webinar will highlight information presented in SAMHSA’s advisory titled, Cannabidiol (CBD) – Potential Harms, Side Effects, and Unknowns, which introduces readers to CBD, how it is derived, and how it differs from other cannabinoids and cannabis products. Participants will learn about the biological and physiological effects of CBD, the risks and harms of CBD use, which include interactions with other drugs and potential risks during pregnancy and fetal development, and common misconceptions about CBD, given its broad availability and marketing for several medical conditions despite limited evidence of efficacy.
Panelists:
Humberto Carvalho – SAMHSA
Substance Abuse & Mental Health Services Administration (SAMHSA)
Krishnan Radhakrishnan – SAMHSA
National Mental Health and Substance Use Policy Laboratory
Substance Abuse & Mental Health Services Administration (SAMHSA)
Krishnan Radhakrishnan, MD, PhD, MPH, Physician, Senior Advisor in the National Mental Health and Substance Use Policy Laboratory (NMHSUPL) within the Substance Abuse and Mental Health Services Administration (SAMHSA) is board certified in public health and general preventive medicine. Dr. Radhakrishnan has broad-based research experiences and published extensively in the clinical, epidemiological, biomedical, biological and physical sciences, supported by extensive computational modeling, data analysis, interpretation and synthesis. He received his BSc (Hons) from Imperial College London, MS from Cornell University and Ph.D. from Massachusetts Institute of Technology (MIT), all in Mechanical Engineering. After several years conducting research at NASA’s Glenn Research Center, focusing on mathematical/computational modeling of combustion, with applications in aero and space propulsion, Dr. Radhakrishnan returned to school, earning his M.D. degree from Case Western Reserve University and MPH from University of Kentucky, Lexington, where he received his residency training in general preventive medicine and public health and served as chief resident and American Cancer Society Fellow, focusing on cancer prevention and control.
Amy Berninger, MPH – Abt Associates
Health Research, Monitoring, and Evaluation Senior Associate
Amy Berninger, MPH, has over 12 years of experience working on a variety of projects related to behavioral health policy that have largely focused on research design, implementation, and evaluation in the areas of substance use disorder prevention and treatment. At Abt Associates, she works on both federal and state research projects for the Substance Abuse and Mental Health Services Administration (SAMHSA), Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality (AHRQ), Massachusetts Department of Public Health, and others. Through this work, Ms. Berninger has supported institutions with efforts to develop and implement policies and procedures that promote substance use prevention and improve capacity to provide effective treatment and recovery support services for individuals with substance use disorders. Ms. Berninger received her MPH in Epidemiology from Boston University School of Public Health.